Class information for:
Level 1: AGALACTOSYL IGG//MABS//PROT ANALYT CHEM

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
4824 1719 40.0 79%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
350 3       COMPLEMENT//MANNOSE BINDING LECTIN//IMMUNOLOGY 35656
1655 2             BIOSIMILAR//FCRN//PROTEIN FORMULATION 6878
4824 1                   AGALACTOSYL IGG//MABS//PROT ANALYT CHEM 1719

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 AGALACTOSYL IGG authKW 230182 1% 72% 18
2 MABS journal 195317 5% 12% 90
3 PROT ANALYT CHEM address 195028 2% 31% 36
4 ANALYT FORMULAT SCI address 194728 1% 44% 25
5 RECOMBINANT MONOCLONAL ANTIBODY authKW 168717 1% 50% 19
6 EFFECTOR FUNCTION authKW 145843 2% 26% 31
7 CE SDS authKW 136624 1% 77% 10
8 CHARGE VARIANTS authKW 111003 1% 63% 10
9 FAB ARM EXCHANGE authKW 110664 1% 69% 9
10 IGG GLYCOSYLATION authKW 106558 1% 50% 12

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Biochemical Research Methods 4684 18% 0% 309
2 Immunology 4268 25% 0% 428
3 Chemistry, Analytical 3106 19% 0% 330
4 Biochemistry & Molecular Biology 2177 32% 0% 549
5 Rheumatology 944 5% 0% 78
6 Medicine, Research & Experimental 648 8% 0% 143
7 Biotechnology & Applied Microbiology 535 9% 0% 152
8 Pharmacology & Pharmacy 223 9% 0% 159
9 Biophysics 91 4% 0% 65
10 Chemistry, Medicinal 57 3% 0% 43

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PROT ANALYT CHEM 195028 2% 31% 36
2 ANALYT FORMULAT SCI 194728 1% 44% 25
3 PROC PROD DEV 96789 2% 21% 26
4 PROC SCI 69086 1% 16% 24
5 PHARMA TECH DEV BIOTECH EUROPE 53285 0% 100% 3
6 PHARMACEUT LIFE SCI GRP 53285 0% 100% 3
7 PHARMA TECH DEV 47944 1% 30% 9
8 BIOMED B14 44399 0% 50% 5
9 ANTIBODY S 40587 0% 29% 8
10 LATE STAGE ANALYT DEV 39962 0% 75% 3

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MABS 195317 5% 12% 90
2 MOLECULAR IMMUNOLOGY 27232 6% 1% 104
3 BIOLOGICALS 3744 1% 1% 17
4 GLYCOBIOLOGY 2991 1% 1% 22
5 GLYCOCONJUGATE JOURNAL 2898 1% 1% 18
6 ANALYTICAL BIOCHEMISTRY 2835 3% 0% 55
7 ANALYTICAL CHEMISTRY 2257 4% 0% 69
8 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 1758 2% 0% 35
9 JOURNAL OF PHARMACEUTICAL SCIENCES 1673 2% 0% 33
10 JOURNAL OF IMMUNOLOGICAL METHODS 1500 2% 0% 29

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 AGALACTOSYL IGG 230182 1% 72% 18 Search AGALACTOSYL+IGG Search AGALACTOSYL+IGG
2 RECOMBINANT MONOCLONAL ANTIBODY 168717 1% 50% 19 Search RECOMBINANT+MONOCLONAL+ANTIBODY Search RECOMBINANT+MONOCLONAL+ANTIBODY
3 EFFECTOR FUNCTION 145843 2% 26% 31 Search EFFECTOR+FUNCTION Search EFFECTOR+FUNCTION
4 CE SDS 136624 1% 77% 10 Search CE+SDS Search CE+SDS
5 CHARGE VARIANTS 111003 1% 63% 10 Search CHARGE+VARIANTS Search CHARGE+VARIANTS
6 FAB ARM EXCHANGE 110664 1% 69% 9 Search FAB+ARM+EXCHANGE Search FAB+ARM+EXCHANGE
7 IGG GLYCOSYLATION 106558 1% 50% 12 Search IGG+GLYCOSYLATION Search IGG+GLYCOSYLATION
8 AFUCOSYLATION 96700 0% 78% 7 Search AFUCOSYLATION Search AFUCOSYLATION
9 FC GLYCOSYLATION 91344 0% 86% 6 Search FC+GLYCOSYLATION Search FC+GLYCOSYLATION
10 GLYCOSYLATION 90825 10% 3% 176 Search GLYCOSYLATION Search GLYCOSYLATION

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 LIU, HC , PONNIAH, G , ZHANG, HM , NOWAK, C , NEILL, A , GONZALEZ-LOPEZ, N , PATEL, R , CHENG, GL , KITA, AZ , ANDRIEN, B , (2014) IN VITRO AND IN VIVO MODIFICATIONS OF RECOMBINANT AND HUMAN IGG ANTIBODIES.MABS. VOL. 6. ISSUE 5. P. 1145 -1154 101 66% 13
2 DALL'OLIO, F , VANHOOREN, V , CHEN, CC , SLAGBOOM, PE , WUHRER, M , FRANCESCHI, C , (2013) N-GLYCOMIC BIOMARKERS OF BIOLOGICAL AGING AND LONGEVITY: A LINK WITH INFLAMMAGING.AGEING RESEARCH REVIEWS. VOL. 12. ISSUE 2. P. 685-698 112 55% 20
3 HMIEL, LK , BRORSON, KA , BOYNE, MT , (2015) POST-TRANSLATIONAL STRUCTURAL MODIFICATIONS OF IMMUNOGLOBULIN G AND THEIR EFFECT ON BIOLOGICAL ACTIVITY.ANALYTICAL AND BIOANALYTICAL CHEMISTRY. VOL. 407. ISSUE 1. P. 79 -94 91 55% 7
4 LIU, HC , NOWAK, C , SHAO, M , PONNIAH, G , NEILL, A , (2016) IMPACT OF CELL CULTURE ON RECOMBINANT MONOCLONAL ANTIBODY PRODUCT HETEROGENEITY.BIOTECHNOLOGY PROGRESS. VOL. 32. ISSUE 5. P. 1103 -1112 83 67% 0
5 REUSCH, D , TEJADA, ML , (2015) FC GLYCANS OF THERAPEUTIC ANTIBODIES AS CRITICAL QUALITY ATTRIBUTES.GLYCOBIOLOGY. VOL. 25. ISSUE 12. P. 1325 -1334 65 60% 21
6 HUHN, C , SELMAN, MHJ , RUHAAK, LR , DEELDER, AM , WUHRER, M , (2009) IGG GLYCOSYLATION ANALYSIS.PROTEOMICS. VOL. 9. ISSUE 4. P. 882-913 94 49% 124
7 BECK, A , WAGNER-ROUSSET, E , AYOUB, D , VAN DORSSELAER, A , SANGLIER-CIANFERANI, S , (2013) CHARACTERIZATION OF THERAPEUTIC ANTIBODIES AND RELATED PRODUCTS.ANALYTICAL CHEMISTRY. VOL. 85. ISSUE 2. P. 715 -736 81 39% 127
8 JEFFERIS, R , (2016) GLYCO-ENGINEERING OF HUMAN IGG-FC TO MODULATE BIOLOGIC ACTIVITIES.CURRENT PHARMACEUTICAL BIOTECHNOLOGY. VOL. 17. ISSUE 15. P. 1333 -1347 79 60% 0
9 EON-DUVAL, A , BROLY, H , GLEIXNER, R , (2012) QUALITY ATTRIBUTES OF RECOMBINANT THERAPEUTIC PROTEINS: AN ASSESSMENT OF IMPACT ON SAFETY AND EFFICACY AS PART OF A QUALITY BY DESIGN DEVELOPMENT APPROACH.BIOTECHNOLOGY PROGRESS. VOL. 28. ISSUE 3. P. 608 -622 87 48% 43
10 LIU, LM , (2015) ANTIBODY GLYCOSYLATION AND ITS IMPACT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MONOCLONAL ANTIBODIES AND FC-FUSION PROTEINS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 104. ISSUE 6. P. 1866 -1884 74 50% 16

Classes with closest relation at Level 1


Rank Class id link
1 33129 IND BIOCHEM PROGRAM//BETA METHYLNORLEUCINE//CX 397
2 2218 GLYCOPROTEOMICS//GLYCOMICS//LECTIN MICROARRAY
3 8514 PROTEIN FORMULATION//PROTEIN AGGREGATION//SUBVISIBLE PARTICLES
4 10008 CD20//OFATUMUMAB//OBINUTUZUMAB
5 10569 FCRN//NEONATAL FC RECEPTOR//TARGET MEDIATED DRUG DISPOSITION
6 30257 ASYMMETRIC ANTIBODIES//CARBOHYDRATE ASSOCIATED EPITOPE//CA215
7 11045 ISOASPARTATE//DEAMIDATION//PROTEIN L ISOASPARTYL METHYLTRANSFERASE
8 3124 FC RECEPTOR//FC GAMMA RECEPTORS//FC GAMMA RECEPTOR
9 27840 CHROMATOFOCUSING//ACID BASE RESIDUES//INDUCED PH GRADIENTS
10 29186 2 TYPES OF LYS DYNAMICS//ANCIENT RNA DNA COMPLEX//C3A COMPLEMENT COMPONENT

Go to start page